Evidence map›Paper›PMID 40398947›Full record

ArticleBMJ open2025

Sulfadoxine-pyrimethamine alone or with azithromycin for the intermittent preventive treatment of malaria in pregnancy: protocol for a systematic review and meta-analysis.

Moussa Lingani, Serge Ouoba, Toussaint Rouamba, Innocent Valea, Maïmouna Sanou, Sékou Samadoulougou, Halidou Tinto, Hermann Sorgho

Abstract read
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Moussa LinganiInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso lingani10@yahoo.fr.ORCID http://orcid.org/0000-0002-5651-2035
Serge OuobaInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.
Toussaint RouambaInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.
Innocent ValeaInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.
Maïmouna SanouUniversité Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
Sékou SamadoulougouInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.
Halidou TintoInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.
Hermann SorghoInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIncreasing METHODS AND ANALYSIS: Eligible studies will be identified through a pre-established search strategy in several electronic databases (Medline, Cochrane Library, Web of Science, EMBASE, WHO International Clinical Trials Registry Platform, ClinicalTrials.gov and AJOL) and will comprise peer-reviewed papers reporting original data on the effects of SP+AZ on the risk of APO. Only randomised controlled trials published until 30 September 2024 in English or French will be included. IPTp with SP+AZ regimens (intervention) will be compared with IPTp with SP alone or with a placebo (control). As primary outcomes, data on the frequency of low birth weight will be collected. Secondary outcomes include the rates of stillbirth, preterm birth, miscarriage and neonatal death. Data will be extracted independently by two reviewers using a predefined extraction form. If the data quality allows for quantitative synthesis, a fixed-effects meta-analysis will be conducted if there is low inter-study heterogeneity. Otherwise, the random-effects meta-analysis will be conducted to take into account uncertainty in pooled estimates that could be due to inter-study heterogeneity. The review protocol was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA-P) guidelines. ETHICS AND DISSEMINATION: Ethical clearance is not needed as the data will be from already published studies in which informed consent and ethical approval were obtained by primary investigators. Our dissemination plan includes the publication in a peer-reviewed journal as well as conference presentations. PROSPERO REGISTRATION NUMBER: CRD42020149592.

Indexed as

AntimalarialsAzithromycinMalariaPregnancy Complications, ParasiticPyrimethamineSulfadoxineDrug CombinationsDrug Therapy, CombinationFemaleHumansInfant, Low Birth WeightInfant, NewbornMeta-Analysis as TopicPregnancyPregnancy OutcomeResearch DesignAntimalarialsAzithromycinDrug Combinationsfanasil, pyrimethamine drug combinationPyrimethamineSulfadoxineClinical TrialMalariaPregnant Women

Identifiers

PMID40398947
PMCPMC12096964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.